The authorization of bortezomib will enhance the company’s ability to deliver advanced cancer solutions in Southeast Asia
Ukrainian marketing approvals for paclitaxel, oxaliplatin and irinotecan mark a significant milestone in the company’s global expansion strategy
These approvals mark significant progress for Venus Remedies in expanding its market presence
The company has received marketing authorisation for docetaxel from Israel and cytarabine from Colombia
Precision medicine company advances Raman spectroscopy-based therapeutic drug monitoring platform for rapid, patient-specific dosing solutions
Notice of Compliance from Health Canada enables marketing authorisation for cancer biosimilar in Canadian market
More than five drug candidates from his team progressed to human trials including drugs like Rilematovir (Phase IIb), and Bedaquiline
Alkem's Pertuza is an affordable, indigenously-developed and manufactured biosimilar of pertuzumab
Utidelone can penetrate BBB due to its unique physicochemical characteristics and insusceptibility to P-glycoprotein-mediated efflux
The company has been entrusted with the responsibility of supplying a wide range of essential oncology drugs
Subscribe To Our Newsletter & Stay Updated
